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A B S T R A C T
Sporadic cases account for 90–95% of all patients with Parkinson's Disease (PD). Atypical Parkinsonism com-
prises approximately 20% of all patients with parkinsonism. Progressive Supranuclear Palsy (PSP) belongs to the
atypical parkinsonian diseases and is histopathologically classiﬁed as a tauopathy. Here, we report that me-
senchymal stem cells (MSCs) derived from the bone marrow of patients with PSP exhibit mitochondrial dys-
function in the form of decreased membrane potential and inhibited NADH-dependent respiration. Furthermore,
mitochondrial dysfunction in PSP-MSCs led to a signiﬁcant increase in mitochondrial ROS generation and oxi-
dative stress, which resulted in decrease of major cellular antioxidant GSH. Additionally, higher basal rate of
mitochondrial degradation and lower levels of biogenesis were found in PSP-MSCs, together leading to a re-
duction in mitochondrial mass. This phenotype was biologically relevant to MSC stemness properties, as it
heavily impaired their diﬀerentiation into adipocytes, which mostly rely on mitochondrial metabolism for their
bioenergetic demand. The defect in adipogenic diﬀerentiation was detected as a signiﬁcant impairment of in-
tracellular lipid droplet formation in PSP-MSCs. This result was corroborated at the transcriptional level by a
signiﬁcant reduction of PPARγ and FABP4 expression, two key genes involved in the adipogenic molecular
network. Our ﬁndings in PSP-MSCs provide new insights into the etiology of ‘idiopathic’ parkinsonism, and
conﬁrm that mitochondrial dysfunction is important to the development of parkinsonism, independent of the
type of the cell.
1. Introduction
In the framework of neurodegenerative diseases, “sporadic” or
“idiopathic” forms of Parkinson's Disease (PD) and to a greater extent
atypical parkinsonian disorders, have been largely neglected due to the
absence of a clear and unequivocal genetic background, such as in fa-
milial monogenic PD [1]. Yet, these forms are notable for their pre-
valence: of 6.3 million PD patients worldwide, “idiopathic” cases ac-
count for 90–95% [2], and atypical parkinsonian disorders represent
20% of total Parkinsonism patients [3].
Atypical parkinsonism comprise a heterogeneous set of disorders
sharing the symptoms found in PD, and sharing the most prominent
pathological hallmark of loss of dopaminergic neurons of the substantia
nigra [4]. Importantly, in contrast to PD, atypical Parkinsonism patients
do not respond, or respond only transiently, to dopamine replacement
therapy [4–6]. Unfortunately, as in “idiopathic” PD forms, no sub-
stantial advances have been made regarding the pathophysiology of
atypical Parkinsonism. At the same time, a growing body of literature
points towards metabolism as a promising avenue that may unravel
novel biological pathways to neurodegeneration [7]. In particular, a
major involvement of mitochondria in the pathological mechanisms of
diverse neurodegenerative diseases is becoming increasingly evident
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[8]. This aspect has already been proven useful at the clinical level,
relying on glucose tissue distribution to diﬀerentiate Parkinsonism
subtypes through metabolic brain imaging [9].
In the context of atypical parkinsonian disorders, progressive su-
pranuclear palsy (PSP), Steele–Richardson–Olszewsky syndrome (SR)
type, belongs to the family of tauopathies, as it involves the accumu-
lation of abnormally phosphorylated tau protein in both neurons and
glia of cortical and subcortical structures [10]. Although a recent
genome-wide association study identiﬁed genetic risk variants for the
development of PSP [11], the genetic background remains necessary
but not suﬃcient to cause this condition (since two-third of the general
non-aﬀected population share this genetic background). The most
consistent genetic association involves the H1 haplotype of the tau
protein-encoding MAPT gene, found in over 90% of the PSP patients
[12]. Intriguingly, whereas levodopa response is poor or absent, PSP
patients have shown slight improvements after treatment with coen-
zyme Q10, a key component of the mitochondrial electron transport
chain (ETC) and a crucial radical-scavenging antioxidant [13]. Very
recently, within a phase I clinical study (trial registration
NCT01824121 at https://clinicaltrials.gov/) we evaluated the safety of
autologous bone marrow mesenchymal stem cell (MSC) administration
to PSP patients to stabilize the progression of the disease, thanks to MSC
paracrine properties [14]. This posed a unique opportunity to address
whether PSP patient-derived MSCs could recapitulate general non-
neural cell aspects of Parkinsonism, such as mitochondrial dysfunction.
For the ﬁrst time in the literature, our study will provide novel insights
on disease mechanisms in the stem cell compartment of these patients
and will investigate its consequences on their diﬀerentiation properties.
Based on this premise, a comprehensive study focused on mi-
tochondrial function was performed to unveil novel metabolism-related
clues that may shed light on PSP pathophysiology. Importantly, to
avoid eﬀects associated with the most acknowledged genetic suscept-
ibility factors, and to obtain data on new pathological mechanisms, we
used MSCs derived only from PSP patients screened against the MAPT
H1 haplotype. With this approach, we aimed at obtaining insights on
“idiopathic” Parkinsonism etiology, which would contribute to a com-
prehensive understanding of parkinsonian disorders as a whole.
2. Materials and methods
2.1. Cell culture
MSCs were isolated from bone marrow (BM) aspirates seeding
50,000 mononucleated cells/cm2 in αMEM (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS;
Thermo Fisher Scientiﬁc), in T75 ﬂasks. The cultures were incubated at
37 °C, 20% O2, 5% CO2. Medium changes were performed twice a week.
Two weeks after initial seeding, primary BMMSC colonies were de-
tached with a 10 min incubation at 37 °C with TrypLE Select Enzyme
(Thermo Fisher Scientiﬁc) and replated at 4000 cells/cm2 in the same
medium. BMMSC identity was previously assessed [29]. Subsequent
passages were performed following the same steps. Passage 4–6
BMMSCs were used for all experiments. BM from Progressive Supra-
nuclear Palsy (PSP) patients was collected in the context of a clinical
protocol authorized by the local Ethics Committee of Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico (Italy), by the national
competent authority for phase-I cell therapy at the National Health
Institute (Istituto Superiore di Sanità) and approved by the Italian
Medicines Agency (Agenzia Italiana del Farmaco, AIFA). The trial is
registered at ClinicalTrials.gov (NCT01824121). BM from healthy do-
nors was collected in the context of the EU-funded REBORNE project.
All BM donors gave their written informed consent.
2.2. Live cell imaging
For identiﬁcation of mitochondrial and lysosomal localization, cells
were loaded with 200 nM MitoTracker Green FM and 50 nM
LysoTracker Red in HBSS for 30 min before experiments. Confocal
images were obtained using a Zeiss 710 confocal microscope equipped
with 40X oil immersion objective. The 488 nm Argon laser line was
used to excite MitoTracker Green ﬂuorescence which was measured
between 505 and 530 nm. Illumination intensity was kept to a
minimum (about 1% of laser output) to avoid phototoxicity and the
pinhole set to give an optical slice of ~2 µm. For LysoTracker Red, the
543 nm Ne/He laser line was used with measurement above 650 nm.
All data presented were obtained from at least 5 coverslips and 2–3
diﬀerent cell preparations.
For measurements of ΔΨm, cells plated on 22 mm glass coverslips
were loaded for 30 min at room temperature with 25 nM tetra-
methylrhodamine methylester (TMRM; Invitrogen) in a HEPES buﬀered
saline solution (HBSS) composed of 156 mM NaCl, 3 mM KCl, 2 mM
MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM
HEPES; pH adjusted to 7.35 with NaOH. The dye remained present in
the media at the time of recording. Confocal images were obtained
using a Zeiss 710 VIS CLSM equipped with a META detection system
and a 40x oil immersion objective. TMRM was excited using the 560 nm
laser line and ﬂuorescence was measured above 580 nm. For basal ΔΨm
measurements, Z-stack images were obtained by confocal microscopy
and analysed using Zeiss software. For analysis of response to mi-
tochondrial toxins, images were recorded continuously from a single
focal plane. TMRM is used in the redistribution mode to assess ΔΨm,
and therefore a reduction in TMRM ﬂuorescence represents mitochon-
drial depolarisation. For measurement of mitochondrial ROS produc-
tion, cells were pre-incubated with MitoTracker Red CM-H(2)XROS for
10 min at room temperature. MitoTracker Red CM-H(2)XROS mea-
surements were produced using 560 nm excitation and emission above
580 nm.
2.3. Measurement of NADH/FAD redox index
NADH autoﬂuorescence was measured using an epiﬂuorescence
inverted microscope equipped with a 20X ﬂuorite objective. Excitation
light at a wavelength of 350 nm was provided by a Xenon arc lamp, the
beam passing through a monochromator (Cairn Research, Kent, UK).
Emitted ﬂuorescence light was reﬂected through a 455 nm long-pass
ﬁlter to a cooled CCD camera (Retiga, QImaging, Canada) and digitized
to 12 bit resolution. Imaging data were collected and analysed using
software from Andor (Belfast, UK). FAD autoﬂuorescence was mon-
itored using a Zeiss 710 VIS CLSM equipped with a META detection
system and a 40x oil immersion objective. Excitation was using the
454 nm Argon laser line and ﬂuorescence was measured from 505 to
550 nm. Illumination intensity was kept to a minimum (at 0.1–0.2% of
laser output) to avoid phototoxicity and the pinhole set to give an op-
tical slice of ~2 µm. FAD and NADH redox indexes and mitochondrial
pools were estimated according the method described in Bartolome
et al. [46].
2.4. Glutathione assessments
Neuronal cultures were incubated with 50 μM monochlorobimane
(MCB) (Molecular Probes, Invitrogen) for 40 min in HEPES buﬀered salt
solution prior to imaging [47]. Cells were then washed with HEPES
buﬀered salt solution and images of the ﬂuorescence of the MCB-GSH
were acquired using a Zeiss 710 CLSM with excitation at 405 nm and
emission at 435–485 nm.
2.5. RNA extraction
Isolation of total RNA was obtained by TRIzol extraction. Brieﬂy,
each sample was lysed directly on the culture dish with 1 mL of TRIzol
reagent (Thermo Fisher Scientiﬁc). Then, 0.2 mL of chloroform was
added and the samples were mixed by inversion, incubated for 5 min
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and centrifuged at 11,000 rpm for 15 min at 4 °C. The resulting RNA-
containing aqueous phase was collected and transferred to a new tube.
Next, 0.5 mL of isopropanol was added. After 10 min incubation, the
samples were centrifuged at 11,000 rpm for 10 min at 4 °C. The su-
pernatant was discarded and the precipitated RNA resuspended in 1 mL
of 75% ethanol, mixed by vortexing and centrifuged at 9000 rpm for
5 min at 4 °C. Finally, the supernatant was discarded and the puriﬁed
precipitated RNA air dried for 10 min and resuspended in 20 μL of
RNase-free water. RNA concentration and quality were determined by
reading the absorbance at 260 nm with a Nanodrop 1000 spectro-
photometer (Thermo Fisher Scientiﬁc) and checking A260/A230 and
A260/A280 ratios. RNA integrity was addressed by agarose gel elec-
trophoresis.
2.6. Real Time qRT-PCR
800 ng of RNA were retrotranscribed using the iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA, USA), following manufacturer's
instructions. Real Time qRT-PCR assays were conducted in triplicate
using SsoFast EvaGreen Supermix (Bio-Rad), following manufacturer's
instructions and preparing 10 μL ampliﬁcation reactions. The thermal
proﬁle used was: 98 °C for 5 min, 46 cycles of 95 °C for 5 s and 60 °C for
20 s. Speciﬁcity of ampliﬁcation was checked by assessing single peak
ampliﬁcation curves. Transcript levels were normalized on TBP and
GAPDH “house-keeping” genes, following the 2ΔΔCt method, using
healthy MSCs as control. Primer sequences for all assays will be given
upon request.
2.7. DNA extraction
Isolation of total DNA was performed by GentraPuregene Blood Kit
(Qiagen, Hilden, Germany), following manufacturer's instructions.
Brieﬂy, cells were lyzed with 300 μL cell lysis solution and vortexed.
Proteins were precipitated with 100 μL protein precipitation solution
and pelleted at 13,000 × g for 1 min. The supernatant was collected,
mixed with 300 μL isopropanol and centrifuged at 13,000 × g for
1 min. The supernatant was discarded and the DNA pellet was washed
with 70% ethanol and centrifuged at 13,000 × g for 1 min. The re-
sulting DNA pellet was resuspended in 50 μL hydration solution. DNA
concentration and quality were assessed by reading the absorbance at
260 nm with a Nanodrop 100 spectrophotometer (Thermo Fisher
Scientiﬁc) and checking A260/A230 and A260/A280 ratios. DNA in-
tegrity was addressed by agarose gel electrophoresis.
2.8. Nuclear DNA sequencing analysis
To analyze genomic DNA extracted from both PSP- and control
MSCs, a targeted resequencing approach using Next-Generation
Sequencing (NGS) technique was implemented. Target enrichment for
all the samples was performed using HaloPlex Target Enrichment
System kit for Illumina Sequencing, 48 rxn (Agilent Technologies, Santa
Clara, CA, USA), according to the manufacturer's protocol. A total of
225 ng genomic DNA per sample was digested in eight diﬀerent re-
striction reactions (30 min incubation at 37 °C). The eight digestion
reactions were combined into a single hybridization mix containing
target speciﬁc probes and a speciﬁc HaloPlex index (8 nt oligonucleo-
tides) for each sample. Each index univocally identiﬁes each sample
during the sequencing. Hybridization reactions were performed in 3-h
incubations at 54 °C. Probes were labeled with biotin and designed to
hybridize to both ends of the digested fragments, therefore generating
circular fragments containing one nick. Then, the DNA probe hybrids
were captured with streptavidin beads to eliminate linear, non-target
DNA fragments. With a ligation reaction, the remaining nicks were
closed to complete circularization. The captured DNA was eluted from
the magnetic beads with 50 mM NaOH and ampliﬁed by PCR reaction,
followed by a ﬁnal puriﬁcation reaction with AMPure XP magnetic
beads (Beckman Coulter, Brea, CA, USA). Finally, the concentration of
each library was measured using 2200 TapeStation instrument (Agilent
Technologies, Santa Clara, CA, USA) and, after the appropriate dilution
of each sample with TE buﬀer, ﬁnal 4 nM libraries were obtained. Then
the libraries were pooled and after further dilutions a 7 pM ﬁnal pool
was obtained (this is the ideal concentration to achieve a cluster density
of about 900/1000 K/mm2 on the ﬂow cell). The ﬁnal puriﬁed, quan-
tiﬁed and pooled multiplex PCR products were sequenced on MiSeq
platform (Illumina, San Diego, CA, USA) with a 2 × 150 bp paired-end
sequencing, using MiSeq reagent kit V2. Target genes analysed were:
SNCA, PARK2, UCHL1, PINK1, DJ1, LRRK2, GBA, VPS35, ATP13A2,
EIF4G1, HTRA2, DNAJC13, VPS13C, DNAJC6, FBXO7, PLA2G6, SYNJ1
and MAPT.
2.9. Mitochondrial DNA sequencing analysis
Molecular analysis was performed on the genomic DNA extracted
from control and PSP-MSCs. According to a standardized protocol, the
entire mitochondrial (mt) DNA was ampliﬁed by PCR into 46 over-
lapping fragments using a set of coupled primers (Variant SEQr™
Resequencing System Applied Biosystems). PCR products were puriﬁed
and each fragment was then sequenced, with two speciﬁc primers M13
forward and reverse, and analysed using an ABI PRISM 3130xl Genetic
Analyzer.
2.10. Evaluation of MSC adipogenic potential
In order to promote diﬀerentiation, a deﬁned adipogenic medium
(Lonza, Basel, Switzerland) was used on MSCs from healthy controls
and PSP patients at passages P3. MSCs were seeded at a density of 3 ×
104 cells/cm2 in αMEM-GlutaMAX (Thermo Fisher Scientiﬁc) with 10%
fetal bovine serum (Thermo Fisher Scientiﬁc). The day after, three cy-
cles of diﬀerentiation induction and maintenance followed. Brieﬂy, the
cycle consisted in 3 days in human MSC Adipogenesis Induction
medium (Lonza), followed by 3 days in human MSC Adipogenesis
Maintenance medium (Lonza). A ﬁnal maintenance cycle of 7 days
concluded the diﬀerentiation protocol, during which medium was
changed every 2–3 days. Then, adipogenic diﬀerentiation was detected
by microscopic observation, and lipid vacuoles were stained with fresh
Oil Red O solution (Sigma-Aldrich, Saint Louis, MI, USA). Brieﬂy, dif-
ferentiated MSCs were washed with PBS (Thermo Fisher Scientiﬁc) and
then ﬁxed with paraformaldehyde (4% in water) for 1 h at RT. After a
washing step with PBS, diﬀerentiated MSCs were stained with fresh Oil
Red O working solution, prepared diluting 3 parts of a 0.5% iso-
propanol stock solution with additional 2 parts of water. Three ﬁnal
washing steps with PBS followed. Finally, Oil Red O incorporation was
quantiﬁed biochemically. To recover Oil Red O, dry wells containing
diﬀerentiated MSCs were incubated with isopropanol for 1 h. To de-
termine the amount of extracted Oil Red O, the absorbance of the
samples were read at 492 nm using a GENios plus plate reader (Tecan,
Männedorf, Switzerland).
2.11. Data and statistical analysis
Data analysis was performed using Origin 8 (Microcal Software Inc.,
Northampton, MA) software. Statistical tests: unpaired two-tailed
Student's tests were performed using GraphPad Prism software
(GraphPad Software, Inc. La Jolla, USA). Diﬀerences were considered
statistically signiﬁcant with p-value<0.01. Results are expressed as
means± standard error of the mean (S.E.M.).
3. Results
3.1. PSP-MSCs exhibit decreased mitochondrial membrane potential
Mitochondrial membrane potential (ΔΨm) is an important indicator
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Fig. 1. Mitochondrial membrane potential is aﬀected in PSP-MSCs. A. Histogram comparing the ΔΨm values of control (black, dark grey) and patients (red) MSC. A1. Images show
mitochondrial networks in control and patient MSCs. ΔΨm was assessed with TMRM (red). Assessment of the mitochondrial respiratory chain function and the maintenance of ΔΨm in
control (B) and patient (B1) MSCs. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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of mitochondrial health. Using TMRM as a ﬂuorescent indicator of
ΔΨm, we found that PSP-MSCs showed signiﬁcantly decreased basal
ΔΨm (Fig. 1, A and A1). Thus, in PSP-MSC 1, ΔΨm was reduced to
69.6±11.0% (n = 20; p<0.001) of the control age-matched MSCs,
and PSP-MSC 2 and PSP-MSC 3–81.4±4.7% (n = 20) and
79.9±9.3% (n = 20) of control, respectively. Therefore, in the context
of PSP, mitochondrial function in stem cells is likely to be impaired.
In the majority of healthy cells, ΔΨm is maintained by the activity of
the mitochondrial respiratory chain. In the event of damage or inhibi-
tion of respiration, cells may maintain mitochondrial membrane po-
tential using ATP hydrolysis by the ATP synthase. In order to in-
vestigate the mechanism of maintenance of ΔΨm, we applied a series of
mitochondrial toxins and observed their eﬀects on ΔΨm. In both control
MSCs, application of oligomycin (2 µg/mL), an inhibitor of the F1F0-
ATPase, induced no response or a slight depolarisation, as proton entry
through the ATP synthase was inhibited. Application of rotenone
(5 µM) to inhibit complex I then produced a profound depolarisation,
and complete depolarisation was estimated by addition of the mi-
tochondrial uncoupler FCCP (1 µM; Fig. 1, B). This indicates that in
control MSCs most of the mitochondrial membrane potential is main-
tained by the respiratory chain. In PSP-MSCs, application of oligomycin
also induced only minor depolarisation (3–5%) or no eﬀect (Fig. 1, B1),
indicating that the ΔΨm is still maintained by the mitochondrial re-
spiratory chain and suggesting that, even under conditions of low ΔΨm,
the ATP synthase in PSP-MSCs is unable to switch to hydrolysis mode.
Importantly, the eﬀect of rotenone on ΔΨm of PSP-MSCs was slower
and smaller compared to control MSCs (from ~60% in control MSCs to
only ~40% in PSP-MSCs), suggesting partial inhibition of the complex I
in the patient MSCs (Fig. 1, B1). Complete depolarisation was achieved
also in PSP-MSCs after FCCP addition (Fig. 1, B1).
3.2. PSP-MSCs demonstrate inhibition of NADH-dependent respiration
In order to investigate mitochondrial respiration speciﬁcally in the
cells with lower ΔΨm and smaller response to rotenone, NADH auto-
ﬂuorescence was measured in PSP- and control MSCs and the redox
index and relative size of the pool of NADH in mitochondria were
calculated. NADH is the electron donor for complex I, and as such,
NADH levels correlate inversely with respiratory chain activity. In order
to measure redox index, we applied FCCP (1 µM) to maximise re-
spiration and therefore minimise the NADH pool, then added NaCN
(1 mM) to block mitochondrial respiration and consequently maximise
the NADH pool. The initial NADH autoﬂuorescence is then calculated as
a percentage of this range (Fig. 2, A). In addition, the total mitochon-
drial pool of NADH may be taken as an indication of the substrate
availability for complex I (Fig. 2, A1).
We observed a signiﬁcant increase in redox levels in PSP-MSCs
(from 47.5± 5.0%, n = 17, for control MSC 1 and 55.2± 10.0%, n =
19, for control MSC 2, to 78.2± 8.3%, n = 10, p = 0.0024, for PSP-
MSC 1, 83.5±10.0%, n = 9, p = 0.0031, for PSP-MSC 2 and
67.9±8.6%, n = 8, p = 0.0396, for PSP-MSC 3; Fig. 2, A), indicating
decreased respiration rate in these cells. The total mitochondrial pool of
NADH in PSP-MSCs was also higher than in control MSCs (from
60.4±10.0%, n = 17, for control MSC 1 and 65.5±20.0%, n = 19,
for control MSC 2, to 90.8±8.9%, n = 10, p=0.0501, for PSP-MSC 1
and 200.0± 10.6%, n = 9, p< 0.0001, for PSP-MSC 2; Fig. 2, A1),
indicating increased substrate availability for complex I of the ETC in
these cells.
3.3. Mitochondrial dysfunction in PSP-MSCs induces signiﬁcant increase in
ROS generation and oxidative stress
Mitochondrial ROS production is linked to the rate of respiration
and therefore also to the mitochondrial membrane potential [15].
Moreover, inhibition of the complex I contributes to higher rates of ROS
production [16]. The basal rates of mitochondrial ROS production, as
measured with the mitochondria-speciﬁc probe MitoTracker Red CM-
H2xROS, diﬀered between the control MSCs and PSP-MSCs (Fig. 3, A,
A1 and B). Thus, the rates of ROS production in PSP-MSC 1, PSP-MSC 2
and PSP-MSC 3 were 3-fold higher (312.6±24.6%, n = 9, p<0.0001,
for PSP-MSC 1, 300.7± 80.1%, n = 11, p = 0.0128, for PSP-MSC 2
and 343.7±17.7%, n = 8, p< 0.0001, for PSP-MSC 3) compared to
control MSC 1 (100.0±0.2%, n = 13; Fig. 3, A1). Such a high level of
ROS production can induce oxidative stress, which results in the re-
duction of the level of major antioxidants. We used monochlorobimane
(MCB) to measure the level of glutathione (GSH). Mitochondrial ROS
overproduction in PSP-MSCs signiﬁcantly decreased the level of GSH in
these cells (36.2± 6.9%, n = 25, p<0.0001, for PSP-MSC 1,
44.7±19.5%, n = 25, p = 0.0167, for PSP-MSC 2 and 46.1±9.4%, n
= 25, p< 0.0001, for PSP-MSC 3) compared to control MSCs
(100.0±0.1%, n = 25, for control MSC 1 and 145.5±9.2%, n = 25,
for control MSC 2; Fig. 3, C). Thus, mitochondrial dysfunction in PSP-
MSCs leads to oxidative stress.
3.4. Basal rate of mitophagy is higher in PSP-MSCs
Cell death is triggered by the release of intramitochondrial proteins,
therefore it is widely accepted that mitochondria are regulators of cell
faith. Considering this, the removal of dysfunctional mitochondria is an
important process for ensuring cell survival. Damaged mitochondria, as
well as other impaired organelles and proteins, are degraded by speciﬁc
mitochondrial autophagy (mitophagy). Deregulation of mitophagy can
lead to an increase in the number of damaged mitochondria that can
induce mitochondrial dysfunction and trigger the activation of cell
death pathways. First, we addressed autophagy protein LC3 gene ex-
pression, which was four-fold higher in PSP- compared to control MSCs
(p< 0.05; Fig. 4, A). Next, to measure the level of mitophagy in PSP
pathology, we estimated the co-localization of the mitochondria (la-
beled with MitoTracker green) with the lysosomes (labeled by Lyso-
Tracker red), which allows us to measure autophagic degradation of
mitochondria independently of any speciﬁc pathways [17]. We have
found that percentage of co-localized mitochondria and lysosomes is
much higher in PSP-MSCs (2.155±0.690%, n = 25, p = 0.1563, for
PSP-MSC 1, 2.205± 0.583%, n = 25, p = 0.1195, for PSP-MSC 2 and
2.345±0.573%, n = 30, p = 0.1062, for PSP-MSC 3), compared to
control MSCs (1.000± 0.100%, n = 15, for control MSC 1 and
1.046±0.280%, n = 20, for control MSC 2; Fig. 4, B). Thus, mi-
tochondrial dysfunction in PSP-MSCs induces higher basal rate of mi-
tophagy.
3.5. Higher rate of mitophagy reduces mitochondrial mass in PSP-MSCs
The number of mitochondria within the cells is regulated by the
balance between mitochondrial biogenesis and mitophagy. Considering
this, for the normal maintenance of the mitochondrial balance, PSP-
MSCs should activate mitochondrial biogenesis. However, the level of
mitochondrial DNA in the cells, measured by PicoGreen ﬂuorescence in
non-nuclear area as an estimation of the number of mitochondria, was
signiﬁcantly lower in PSP-MSC 1 (68.5±4.1%, n = 35, p<0.0001),
PSP-MSC 2 (74.6±7.1%, n = 25, p = 0.0026) and PSP-MSC 3
(62.7±5.5%, n = 15, p<0.0001) compared to control MSC 1
(100.0±0.2%, n = 20) and 2 (80.5±6.3%, n = 30); (Fig. 5, A). Total
mitochondrial mass (estimated as the total TMRM density in aU per
area of the cell) was as well signiﬁcantly lower in PSP-MSC 1
(454.2±133.5, n = 30, p = 0.0215), PSP-MSC 2 (287.1± 123.4, n =
25, p = 0.0014) and PSP-MSC 3 (407.1± 159.3, n = 25, p = 0.0206),
compared to control MSC 1 (910.3±137.0, n = 25) and control MSC 2
(871.1±119.0, n = 25), as shown in Fig. 5, B). In accordance with
these results, the gene expression level of mitochondrial biogenesis
master regulator PGC1α was ﬁve-fold higher in control compared to
PSP- MSCs (Fig. 5, C).
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3.6. PSP phenotype arises independently of known parkinsonism-related
mutations
To address genetic mutations already known to participate in the
development of PD or other parkinsonian pathologies, both nuclear and
mtDNA were analysed. Next-generation sequencing revealed no muta-
tions in a selected group of 18 genes known in the literature to be in-
volved in the pathogenesis of the genetic forms of PD and other par-
kinsonian diseases. Synonymous or nonsynonymous single nucleotide
variants known to be single nucleotide polymorphisms or benign var-
iants were observed. Minor variants with uncertain clinical relevance
were found in both PSP- and control MSCs. Similarly, sequencing
analysis of the entire mtDNA did not reveal pathogenic mutations
among all PSP- and control MSCs. Several homoplasmic variants were
detected, which, again, are known to be benign polymorphisms. Thus,
no known genetic mutation determines the observed PSP phenotype.
3.7. PSP-MSCs show impaired diﬀerentiation properties compared to age-
matched healthy controls
Based on the hypothesis that mitochondrial activity is pivotal for
MSC diﬀerentiation capability, adipogenic potential was assessed,
being the most energy-demanding diﬀerentiation process that mainly
relies on mitochondrial activity. After a 3 weeks diﬀerentiation protocol
on a large group of PSP-MSCs (n = 8) and age-matched healthy control
MSCs (n = 6), adipogenic diﬀerentiation was evaluated by Oil Red O
Fig. 2. PSP leads to inhibition of NADH-dependent respiration. A. Quantiﬁcation of the NADH redox index from control (black, dark grey) and patient MSCs (red). A1. NADH pool,
calculated from control (black, dark grey) and patient MSCs (red). Representative traces from control (black traces, B) or patient MSCs (red traces, B1) NADH autoﬂuorescence.
Application of 1 µM fccp maximizes respiration and addition of 1 mM NaCN fully inhibits mitochondrial respiration. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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staining and by biochemical quantiﬁcation of its incorporation into
diﬀerentiated cells. As shown in Fig. 6A1, control MSCs diﬀerentiated
steadily and homogeneously into mature adipocytes, containing Oil Red
O-positive large fat droplets. On the other hand, PSP-MSCs failed to
reach full adipogenic diﬀerentiation, presenting fewer Oil Red O-posi-
tive adipocytes and smaller fat deposits. Biochemical quantiﬁcation of
incorporated Oil Red O in the diﬀerent samples conﬁrmed more accu-
rately this result, demonstrating that PSP-MSCs had signiﬁcantly re-
duced adipogenic potential compared to control MSCs (p< 0.005).
Moreover, this aspect was conﬁrmed at the gene expression level.
Adipogenesis regulators PPARγ and FABP4 were signiﬁcantly down-
regulated in PSP- compared to control MSCs (p<0.005 and p< 0.05,
respectively; Fig. 6C).
4. Discussion
Stem cell metabolism is a growing area of research in the stem cell
ﬁeld. The inﬂuence of mechanisms of energy production on stem cell
physiology and disease is increasingly recognized. Speciﬁcally, meta-
bolism has been associated with stem cell self-renewal and diﬀer-
entiation control. For instance, high glucose was shown to suppress
embryonic stem cell diﬀerentiation into neural cells [18]; hypoxia was
shown to sustain stemness by inhibition of oxidative phosphorylation
and increased glycolysis by activation of HIF-1α and consequent in-
hibition of pyruvate dehydrogenase kinase activity [19]. Intriguingly, it
was also observed that, during stem cell asymmetric divisions, old
mitochondria segregate with daughter cells fated to diﬀerentiation,
whereas during symmetric divisions new and old mitochondria are
equally distributed [20]. This way, mitochondria themselves appear to
play a central role in stem cell fate decisions. Concerning the inﬂuence
of mitochondria on MSC diﬀerentiation potential, it was demonstrated
that mitochondrial respiration inﬂuences adipogenic properties of
MSCs. Indeed, increased mitochondrial activity is a prerequisite for the
maturation of adipocytes from MSCs, since the knockdown of the mi-
tochondrial transcription factors resulted in the inhibition of adipo-
genesis in MSCs [21]. Furthermore, a study recently showed that adi-
pogenesis diﬀerentiation involves MSC mitochondrial fusion and
consequent increased expression of fusion protein Mfn 1 and 2 [22].
In this context, the metabolism of MSCs of neurodegenerative dis-
ease patients has still not been addressed, until now. Understanding the
basis of the crosstalk between mitochondria and cell fate is of critical
importance, given the promising application of stem cells in re-
generative medicine. Furthermore, MSCs are widely recognized as
regulators of tissue homeostasis [23], and it is therefore of utmost im-
portance to determine the inﬂuence of neurodegenerative-associated
metabolism on stem cell function. Some reports have shown widespread
systemic involvement for speciﬁc neurodegenerative diseases, where
non-neural cells are aﬀected or inﬂuenced the pathological neuronal
loss. For instance, alterations in metalloproteases, crucial actors in
tissue remodeling and stem cell mobilization, were found in the MSC
compartment in amyotrophic lateral sclerosis (ALS) patients [24]. A
further two studies demonstrated a correlation between ALS progres-
sion rate and impaired MSC function [25,26], reporting that functional
deﬁciencies in MSCs were proportional to disease progression.
Fig. 3. Increased ROS production and decreased GSH levels in PSP-MSCs. Representative traces for the rate of mitochondrial reactive oxygen species (ROS) generation (A.) and
quantiﬁcation of these experiments (A1.) in patient (light green, green, olive) and control (black, dark grey) MSCs. B. Representative images of control and patient MSCs, labeled with
MitoTracker Red CM-H2XROS. B1. Levels of Glutathione (GSH), assessed by MCB ﬂuorescence- controls (black, dark grey) and patient MSCs (teal). (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
P.R. Angelova et al. Redox Biology 14 (2018) 474–484
480
Moreover, MSC impaired functionality was also observed in multiple
sclerosis (MS) patients [27]. In detail, conditioned media from MSCs of
patients with long duration of progressive disease showed reduced
neuroglial protective capacity. This observation led to the identiﬁcation
by mass spectrometry of 40 factors whose secretion was altered in
progressive MS. Finally, hTERT-immortalized adipose tissue-derived
MSCs from idiopathic or familial PD patients showed decreased activity
in mitochondrial complexes I, II and IV [28], suggesting that such cells
could represent a good model to study mitochondrial dysfunctions of
PD pathogenesis and treatment.
Thus, this study represents the ﬁrst in its eﬀort to describe the ef-
fects of a parkinsonian disease in the bone marrow stem cell compart-
ment, from the perspective of MSC bioenergetics. The rationale of the
study was to evaluate if metabolic dysfunction observed in the mi-
tochondria in patient neurons were also present in a distant stem cell
compartment. This study is of paramount importance, due to the
Fig. 4. Basal mitophagy rate is increased in PSP-MSCs. A. Representative images of lysosomes labeled with LysoTracker Red (red) and mitochondria with MitoTracker Green (green).
Merging of both signals is counted as a mitophagy event. A1. Histogram showing co-localization of LysoTracker Red with MitoTracker Green in control (black, dark grey) and patient
(red) MSCs, as a sign of early mitophagy. B. Transcription levels of LC3 in control and PSP patient's MSCs. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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currently proposed use of autologous MSCs in the treatment of neuro-
degenerative diseases [29]. Indeed, our data indicate that MSCs from
the bone marrow of PSP patients show impaired mitochondrial func-
tionality, still in the context of useful neuroprotective factor secretion.
Therefore, their use in preliminary clinical studies should be thoroughly
evaluated, taking into account also their metabolic state, which could
be correlated to clinical outcome eﬀectiveness.
Speciﬁcally, we observed a decrease in the mitochondrial mem-
brane potential of PSP patient MSCs (PSP-MSCs) and an increase of
NADH redox state, suggesting a partial inhibition of complex I, as
already described by some reports for PSP patients [30]. Importantly,
this hypothesis was conﬁrmed in further experiments, where the eﬀect
of complex I inhibitor rotenone on mitochondrial membrane potential
was signiﬁcantly lower in PSP-MSCs. Mitochondrial membrane poten-
tial in these conditions was still predominantly maintained by electron
transport chain (by activation of the complex II, a mechanism reported
by the literature [31–35] and also by others) due to almost similar re-
sponses to ATP synthase inhibitor oligomycin and much larger re-
sponses to an uncoupler agent. In all the experiments the comparison to
healthy age-matched bone marrow donors allowed us to exclude the
Fig. 5. Mitochondrial biogenesis is decreased or insuﬃcient in PSP-MSCs. A. Mitochondrial DNA content was decreased as measured by PicoGreen ﬂuorescence. A1 Representative
images of the mtDNA content in control and patient MSCs. B.Mitochondrial mass is signiﬁcantly reduced in patient MSCs. C. transcription levels of the PGC1α in control and PSP patient's
MSCs.
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possibility that the observed results were related to an age-speciﬁc
phenotype.
Activation of the complex II in the context of partial inhibition of
mitochondrial complex I can lead to increased production of ROS in
mitochondria [16,36]. Although mitochondrial ROS can play a phy-
siological role [37], extremely high ROS production in mitochondria of
PSP-MSCs induced high levels of oxidative stress, which resulted in a
signiﬁcant decrease of the major endogenous antioxidant GSH.
Oxidative damage can trigger mitophagy, a form of mitochondria-
speciﬁc autophagy [38–43]. In PSP-MSCs, higher co-localization of the
mitochondria and lysosomes was observed suggesting a higher rate of
mitophagy compared to age-matched healthy controls. This diﬀerence
could be due to the aforementioned mitochondria-driven oxidative
stress. This higher rate of mitophagy was coupled with a decreased or
insuﬃcient rate of mitochondrial biogenesis, which led to an overall
lower mitochondrial content in PSP-MSCs.
Given the crucial role played by healthy mitochondria on adipo-
genic diﬀerentiation, as earlier described, we tested if impaired mi-
tochondrial activity could have detrimental eﬀects on PSP-MSC prop-
erties. Strikingly, all PSP-MSCs showed a reduced capacity to generate
fully diﬀerentiated adipocytes, conﬁrming for the ﬁrst time the im-
pairment of the stem cell compartment diﬀerentiation properties in a
parkinsonian disease.
It is important to note that a lower mitochondrial density in com-
bination with inhibition of mitochondrial complex I is not enough to
induce severe pathology of energy metabolism under resting condi-
tions. Yet it may be limiting and pathological under the increased en-
ergy demand of diﬀerentiation to speciﬁc cells, such as adipocytes or
functional neurons.
It is reported in the literature that PSP pathology is related to mi-
tochondrial complex I dysfunction. In the absence of a known mutation,
as in our samples screened against the main MAPT gene PSP-associated
H1 haplotype, it is possible that minor mutations at the mtDNA level
could negatively inﬂuence complex I activity, as proposed by some
reports [30,44,45]. In these studies, transmitochondrial cytoplasmic
hybrids (cybrids) cell lines, expressing PSP mtDNA, recapitulated a
bioenergetic defect similar to that of PSP cells: higher oxidative stress,
higher anti-oxidant activity, impaired complex I activity. Notwith-
standing, we cannot exclude that the nature of such defects could be
that of a “secondary” damage related to systemic consequences of the
neurodegenerative disease localized at the brain tissue, rather than a
“primary” damage, directly associated to PSP aetiopathology. Yet, no
relevant genomic alterations were found in nuclear or mitochondrial
DNA of our samples, which could be attributed to the development of
the parkinsonian disease phenotype.
In conclusion, despite the traditional view of Parkinsonism as cen-
tral nervous system diseases, here, for the ﬁrst time in the literature, we
unexpectedly detected severe mitochondrial function impairment in
stem cells isolated from the bone marrow of PSP patients. Therefore,
our conclusion is that crucial metabolic aspects of parkinsonian dis-
orders are indeed recapitulated at the systemic level, in compartments
other than the nervous system.
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